Northeast Pharmaceutical Group Co Ltd (000597) - Net Assets

Latest as of March 2026: CN¥5.68 Billion CNY ≈ $831.86 Million USD

Based on the latest financial reports, Northeast Pharmaceutical Group Co Ltd (000597) has net assets worth CN¥5.68 Billion CNY (≈ $831.86 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥13.59 Billion ≈ $1.99 Billion USD) and total liabilities (CN¥7.91 Billion ≈ $1.16 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Northeast Pharmaceutical Group Co Ltd tangible equity quality to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥5.68 Billion
% of Total Assets 41.83%
Annual Growth Rate 8.23%
5-Year Change 32.14%
10-Year Change 132.92%
Growth Volatility 22.43

Northeast Pharmaceutical Group Co Ltd - Net Assets Trend (1993–2025)

This chart illustrates how Northeast Pharmaceutical Group Co Ltd's net assets have evolved over time, based on quarterly financial data. See 000597 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Northeast Pharmaceutical Group Co Ltd (1993–2025)

The table below shows the annual net assets of Northeast Pharmaceutical Group Co Ltd from 1993 to 2025. For live valuation and market cap data, see Northeast Pharmaceutical Group Co Ltd (000597) market capitalisation.

Year Net Assets Change
2025-12-31 CN¥5.67 Billion
≈ $829.59 Million		 +1.79%
2024-12-31 CN¥5.57 Billion
≈ $815.01 Million		 +7.97%
2023-12-31 CN¥5.16 Billion
≈ $754.89 Million		 +9.45%
2022-12-31 CN¥4.71 Billion
≈ $689.70 Million		 +9.86%
2021-12-31 CN¥4.29 Billion
≈ $627.80 Million		 +4.08%
2020-12-31 CN¥4.12 Billion
≈ $603.21 Million		 +5.22%
2019-12-31 CN¥3.92 Billion
≈ $573.30 Million		 +9.05%
2018-12-31 CN¥3.59 Billion
≈ $525.75 Million		 +41.01%
2017-12-31 CN¥2.55 Billion
≈ $372.85 Million		 +4.68%
2016-12-31 CN¥2.43 Billion
≈ $356.17 Million		 +1.37%
2015-12-31 CN¥2.40 Billion
≈ $351.34 Million		 -13.04%
2014-12-31 CN¥2.76 Billion
≈ $404.05 Million		 +72.68%
2013-12-31 CN¥1.60 Billion
≈ $233.99 Million		 -8.64%
2012-12-31 CN¥1.75 Billion
≈ $256.13 Million		 +0.43%
2011-12-31 CN¥1.74 Billion
≈ $255.03 Million		 -15.62%
2010-12-31 CN¥2.07 Billion
≈ $302.24 Million		 +0.58%
2009-12-31 CN¥2.05 Billion
≈ $300.50 Million		 +30.42%
2008-12-31 CN¥1.57 Billion
≈ $230.40 Million		 +77.07%
2007-12-31 CN¥889.22 Million
≈ $130.12 Million		 -4.13%
2006-12-31 CN¥927.49 Million
≈ $135.72 Million		 +3.05%
2005-12-31 CN¥900.07 Million
≈ $131.71 Million		 +1.82%
2004-12-31 CN¥884.02 Million
≈ $129.36 Million		 +1.58%
2003-12-31 CN¥870.26 Million
≈ $127.35 Million		 -0.35%
2002-12-31 CN¥873.28 Million
≈ $127.79 Million		 -1.14%
2001-12-31 CN¥883.36 Million
≈ $129.26 Million		 -2.45%
2000-12-31 CN¥905.53 Million
≈ $132.51 Million		 +4.12%
1999-12-31 CN¥869.73 Million
≈ $127.27 Million		 -12.95%
1998-12-31 CN¥999.14 Million
≈ $146.21 Million		 +6.82%
1997-12-31 CN¥935.36 Million
≈ $136.87 Million		 -5.95%
1996-12-31 CN¥994.58 Million
≈ $145.54 Million		 +28.32%
1995-12-31 CN¥775.11 Million
≈ $113.42 Million		 +59.11%
1994-12-31 CN¥487.14 Million
≈ $71.28 Million		 +8.00%
1993-12-31 CN¥451.06 Million
≈ $66.00 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Northeast Pharmaceutical Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 3020.1% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Retained Earnings CN¥1.37 Billion 24.83%
Other Components CN¥4.16 Billion 75.17%
Total Equity CN¥5.53 Billion 100.00%

Northeast Pharmaceutical Group Co Ltd Competitors by Market Cap

The table below lists competitors of Northeast Pharmaceutical Group Co Ltd ranked by their market capitalization.

Company Market Cap
Kayne Anderson BDC, Inc.
NYSE:KBDC
 $916.96 Million
Jiangsu Riying Electns Co Ltd
SHG:603286
 $917.00 Million
Lotte Tour Dev
KO:032350
 $917.06 Million
Yunnan Hongxiang Yixintang
SHE:002727
 $917.76 Million
Shanghai Baolong Automotive Corp
SHG:603197
 $916.69 Million
BP PLC
LSE:BP
 $916.43 Million
Changchun Zhiyuan New Energy Equipment Co. Ltd
SHE:300985
 $915.67 Million
Colorlight Cloud Tech Ltd. A
SHE:301391
 $915.56 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Northeast Pharmaceutical Group Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 5,321,613,000 to 5,529,861,665, a change of 208,248,665 (3.9%).
  • Net income of 260,070,457 contributed positively to equity growth.
  • Dividend payments of 196,902,897 reduced retained earnings.
  • Other comprehensive income decreased equity by 8,970,433.
  • Other factors increased equity by 154,051,538.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income CN¥260.07 Million +4.7%
Dividends Paid CN¥196.90 Million -3.56%
Other Comprehensive Income CN¥-8.97 Million -0.16%
Other Changes CN¥154.05 Million +2.79%
Total Change CN¥- 3.91%

Book Value vs Market Value Analysis

This analysis compares Northeast Pharmaceutical Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.13x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 6.58x to 1.13x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1993-12-31 CN¥0.67 CN¥4.39 x
1994-12-31 CN¥0.72 CN¥4.39 x
1995-12-31 CN¥1.15 CN¥4.39 x
1996-12-31 CN¥1.47 CN¥4.39 x
1997-12-31 CN¥1.38 CN¥4.39 x
1998-12-31 CN¥1.22 CN¥4.39 x
1999-12-31 CN¥1.29 CN¥4.39 x
2000-12-31 CN¥1.29 CN¥4.39 x
2001-12-31 CN¥1.27 CN¥4.39 x
2002-12-31 CN¥1.29 CN¥4.39 x
2003-12-31 CN¥1.29 CN¥4.39 x
2004-12-31 CN¥1.31 CN¥4.39 x
2005-12-31 CN¥1.33 CN¥4.39 x
2006-12-31 CN¥1.38 CN¥4.39 x
2007-12-31 CN¥1.31 CN¥4.39 x
2008-12-31 CN¥2.29 CN¥4.39 x
2009-12-31 CN¥2.73 CN¥4.39 x
2010-12-31 CN¥2.73 CN¥4.39 x
2011-12-31 CN¥2.23 CN¥4.39 x
2012-12-31 CN¥1.85 CN¥4.39 x
2013-12-31 CN¥2.03 CN¥4.39 x
2014-12-31 CN¥3.03 CN¥4.39 x
2015-12-31 CN¥2.17 CN¥4.39 x
2016-12-31 CN¥2.19 CN¥4.39 x
2017-12-31 CN¥2.30 CN¥4.39 x
2018-12-31 CN¥2.86 CN¥4.39 x
2019-12-31 CN¥3.01 CN¥4.39 x
2020-12-31 CN¥3.25 CN¥4.39 x
2021-12-31 CN¥3.07 CN¥4.39 x
2022-12-31 CN¥3.38 CN¥4.39 x
2023-12-31 CN¥3.48 CN¥4.39 x
2024-12-31 CN¥3.72 CN¥4.39 x
2025-12-31 CN¥3.87 CN¥4.39 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Northeast Pharmaceutical Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 4.70%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 3.68%
  • • Asset Turnover: 0.55x
  • • Equity Multiplier: 2.33x
  • Recent ROE (4.70%) is above the historical average (2.87%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1993 9.76% 4.39% 0.67x 3.33x CN¥-1.09 Million
1994 12.98% 6.76% 0.58x 3.28x CN¥14.51 Million
1995 6.08% 4.49% 0.43x 3.16x CN¥-30.41 Million
1996 2.01% 1.71% 0.38x 3.11x CN¥-79.51 Million
1997 -7.40% -9.14% 0.35x 2.32x CN¥-162.78 Million
1998 4.31% 4.67% 0.29x 3.14x CN¥-46.90 Million
1999 4.99% 4.29% 0.39x 2.99x CN¥-43.58 Million
2000 2.23% 1.63% 0.45x 3.06x CN¥-67.73 Million
2001 0.44% 0.27% 0.52x 3.20x CN¥-82.32 Million
2002 1.11% 0.69% 0.52x 3.07x CN¥-77.65 Million
2003 1.00% 0.54% 0.64x 2.90x CN¥-78.34 Million
2004 0.68% 0.37% 0.67x 2.75x CN¥-82.41 Million
2005 1.38% 0.68% 0.80x 2.55x CN¥-77.59 Million
2006 2.65% 1.17% 0.95x 2.38x CN¥-68.16 Million
2007 5.36% 1.28% 1.21x 3.44x CN¥-41.22 Million
2008 22.77% 7.76% 1.12x 2.61x CN¥200.75 Million
2009 23.58% 9.35% 0.84x 3.01x CN¥274.16 Million
2010 2.64% 1.11% 0.86x 2.77x CN¥-148.89 Million
2011 -23.79% -10.15% 0.66x 3.54x CN¥-560.00 Million
2012 0.49% 0.21% 0.64x 3.60x CN¥-158.42 Million
2013 -11.11% -4.31% 0.51x 5.02x CN¥-317.30 Million
2014 3.27% 2.01% 0.51x 3.22x CN¥-179.36 Million
2015 -16.79% -10.02% 0.44x 3.80x CN¥-613.28 Million
2016 1.03% 0.49% 0.49x 4.23x CN¥-207.66 Million
2017 4.89% 2.10% 0.54x 4.35x CN¥-124.37 Million
2018 5.62% 2.61% 0.64x 3.38x CN¥-151.88 Million
2019 4.57% 2.12% 0.66x 3.29x CN¥-207.10 Million
2020 0.31% 0.17% 0.61x 3.06x CN¥-385.80 Million
2021 2.39% 1.22% 0.62x 3.18x CN¥-315.35 Million
2022 7.68% 3.98% 0.64x 3.03x CN¥-105.68 Million
2023 7.19% 4.35% 0.54x 3.06x CN¥-140.37 Million
2024 7.70% 5.46% 0.52x 2.71x CN¥-122.31 Million
2025 4.70% 3.68% 0.55x 2.33x CN¥-292.92 Million

Industry Comparison

This section compares Northeast Pharmaceutical Group Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $3,753,541,490
  • Average return on equity (ROE) among peers: 4.10%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Northeast Pharmaceutical Group Co Ltd (000597) CN¥5.68 Billion 9.76% 1.39x $916.75 Million
Shenzhen Neptunus Bioengineering Co Ltd (000078) $1.97 Billion 4.04% 0.54x $565.97 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $654.09 Million 2.17% 0.78x $359.03 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $0.00 0.00% 0.00x $4.30 Billion
Livzon Pharmaceutical Group Inc (000513) $973.90 Million 0.17% 0.60x $2.52 Billion
Wedge Industrial Co Ltd (000534) $1.29 Billion 11.69% 1.47x $2.41 Billion
Yunnan Baiyao Group Co Ltd (000538) $3.19 Billion 14.61% 0.55x $12.64 Billion
Hainan Haiyao Co Ltd (000566) $353.98 Million -9.58% 0.80x $715.72 Million
Tus Pharmaceutical Group Co Ltd (000590) $307.22 Million 6.68% 0.79x $319.94 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $25.04 Billion 7.11% 0.16x $3.00 Billion

About Northeast Pharmaceutical Group Co Ltd

SHE:000597 China Drug Manufacturers - Specialty & Generic
Market Cap
$916.75 Million
CN¥6.26 Billion CNY
Market Cap Rank
#9447 Global
#2457 in China
Share Price
CN¥4.39
Change (1 day)
+0.00%
52-Week Range
CN¥4.38 - CN¥6.49
All Time High
CN¥133.00
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

Northeast Pharmaceutical Group Co., Ltd. engages in chemical pharmaceuticals manufacturing, pharmaceutical distribution, pharmaceutical engineering, biopharmaceuticals, and other businesses in China. It offers vitamin products, such as vitamin C, vitamin B1, vitamin B6, and L-carnitine series; anti- infective products, such as fosfomycin series, azithromycin series, amantadine series, polyalkali … Read more